Clinical Trial Update: Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ibudilast (MN-166) in subjects with amyotrophic lateral sclerosis has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• ibudilast (ibudilast)

Snippet

Sponsor: MediciNova | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2021-11-05